Field, J.K. (J. K.)
- Publications
- item.page.relationships.isContributorAdvisorOfPublication
- item.page.relationships.isContributorOfPublication
4 results
Search Results
Now showing 1 - 4 of 4
- Consensus statements from the Second International Lung Cancer Molecular Biomarkers Workshop: a European strategy for developing lung cancer molecular diagnostics in high risk populations(Spandidos Publications, 2002) Tockman, M. (M.); Pullen, J. (J.); Lachmann, P. (P.); Herman, J. (J.); Tyndale, R. (R.); Field, J.K. (J. K.); Henschke, C.I. (C.I.); Maier, S. (S.); Youngson, J. (J.); Mulshine, J.L. (James L.); Montuenga-Badia, L.M. (Luis M.); Murphy, M. (Murphy); Caporaso, N.E. (Neil E.); Spitz, M.R. (Margaret R.); Lam, S. (S.); Wistuba, I.I. (Ignacio I.); Hirsch, F. (F.); Flahault, A. (A.); Brambilla, C. (C.)The Second Molecular Biomarkers Workshop was held at the Roy Castle International Centre for Lung Cancer Research in Liverpool, in June 2001 and it brought together experts in the clinical, epidemiological and molecular-pathology of lung cancer from Europe and the USA, to address issues surrounding the development of a European strategy for early lung cancer detection. The 2001 Workshop Breakout Groups concentrated on the current challenges in the early detection of lung cancer which need to be addressed in the light of the recent surge in interest in many countries for mounting new clinical trials to evaluate the utility of Spiral CT in early lung cancer detection. If population-based trials of CT screening are mounted it will also be a favorable clinical environment in which to evaluate efficiently recent advances in molecular screening and genotyping. The Workshop focused specifically on: a) clinical and molecular biomarkers, b) sputum as an early detection and diagnostic tool, c) validation of molecular markers prior to their use in early detection trials and d) ethical issues that have to be considered in early lung cancer detection trials. A distillation of the Workshop discussions is given in this article.
- Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project.(American Thoracic Society, 2009-03-01) EUELC; Roz, L. (Luca); Bossi, P. (P.); Vesin, A. (Aurelien); Liloglou, T. (Triantafillos); Andriani, F. (F.); Calabro, E. (E); Field, J.K. (J. K.); Tosi, D. (Diego); Conte, D. (D.); Tavecchio, L. (Luca); Brambilla, E. (E.); Livio, A. (Anna); Mancini, A. (Andrea); Sozzi, G. (Gabriella); Calarco, G. (G.); Brambilla, C. (C.); Verri, C. (Carla)Rationale: Fragile histidine triad (FHIT) is a tumor suppressor gene involved in the pathogenesis of lung cancer. Objectives: The purpose of this study was to investigate the different molecular alterations leading to the inactivation of FHIT gene function and to validate their use as biomarkers of risk for progression of the disease in patients belonging to the multicentric European study for the Early detection of Lung Cancer (EUELC) who were resected for early-stage lung tumors. Methods: FHIT immunostaining was performed on 305 tumor samples. Themethylation status of FHIT promoterwas assessed by nested methylation-specific polymerase chain reaction (MSP-PCR) in 232 tumor and 225 normal lung samples ofwhich a subset of 187 patients had available normal/tumorDNA pairs. Loss of heterozygosity (LOH) at the FHIT locus was analyzed in 202 informative cases by D3S1300 and D3S1234 microsatellite markers. Measurements and Main Results: Lost or reduced FHIT expression was found in 36.7 and 75.7% of the tumor samples, respectively. Methylation of the FHIT promoter was found in 36.7%of tumor and 32.7% of normal lung samples, whereas LOH was detected in 61.9% of the tumors. A strong association with complete loss of FHIT expression was presentwhenmethylation and LOHwere analyzed together (P5 0.0064). Loss of FHIT protein expression was significantly more frequent in squamous cell carcinoma histotype (P , 0.0001) and in smokers (P5 0.008). FHIT methylation in normal lung was associated with an increased risk of progressive disease (OR, 2.27; P 5 0.0415). Conclusions:Our results indicate thatdifferentmolecularmechanisms interplay to inactivate FHIT expression and support the proposition that FHIT methylation in normal lung tissue could represent a prognostic marker for progressive disease.
- EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration. European Respiratory(European Respiratory Society, 2009-05-15) Pajares, M.J. (María José); Niklinski, J. (J.); Vignaud, J.M. (J.M.); Lozano, M.D. (María Dolores); EUELC; Niaz, A. (A.); Hainaut, P. (P.); Roz, L. (Luca); Vesin, A. (Aurelien); Liloglou, T. (Triantafillos); Elborn, J. (J.S.); Field, J.K. (J. K.); Prinsen, C. (C.); Gosney, J.R. (J. R.); Giles, T. (T.); Montuenga-Badia, L.M. (Luis M.); Brambilla, E. (E.); Sozzi, G. (Gabriella); Magee, N.D. (N.D.); Bryan, J. (J.); Cassidy, A. (A.); Thunnissen, F.B. (Frederick B.); Martinet, Y. (Y.); Risch, A. (A.); O'Byrne, K.J. (K.J.); Snijders, P.J. (P.J.); Harrison, D.J. (D. J.); Timsit, J.F. (J.F.); Becker, H. (H.D.); Smit, E.F. (E.F.); Brambilla, C. (C.)The European Early Lung Cancer (EUELC) project aims to determine if specific genetic alterations occurring in lung carcinogenesis are detectable in the respiratory epithelium. In order to pursue this objective, nonsmall cell lung cancer (NSCLC) patients with a very high risk of developing progressive lung cancer were recruited from 12 centres in eight European countries: France, Germany, southern Ireland, Italy, the Netherlands, Poland, Spain and the UK. In addition, NSCLC patients were followed up every 6 months for 36 months. A European Bronchial Tissue Bank was set up at the University of Liverpool (Liverpool, UK) to optimise the use of biological specimens. The molecular–pathological investigations were subdivided into specific work packages that were delivered by EUELC Partners. The work packages encompassed mutational analysis, genetic instability, methylation profiling, expression profiling utilising immunohistochemistry and chip-based technologies, as well as in-depth analysis of FHIT and RARb genes, the telomerase catalytic subunit hTERT and genotyping of susceptibility genes in specific pathways. The EUELC project engendered a tremendous collaborative effort, and it enabled the EUELC Partners to establish protocols for assessing molecular biomarkers in early lung cancer with the view to using such biomarkers for early diagnosis and as intermediate end-points in future chemopreventive programmes.
- Recommendations for implementing lung cancer screening with low-dose computed tomography in Europe(MDPI AG, 2020) Bonomo, L. (Lorenzo); Rossi, A. (Alexia); Vittorio-Scagliotti, G. (Giorgio); Brain, K. (Kate); Senan, S. (Suresh); Ferrante, G. (Giuseppe); Valentino-Infante, M. (Maurizio); Van-Meerbeeck, J.P. (Jan P.); Horgan, D. (Denis); Rocco, G. (Gaetano); Baldwin, D.R. (David R.); Rampinelli, C. (Cristiano); Triphuridet, N. (Natthaya); Ghislandi, S. (Simone); Field, J.K. (J. K.); Henschke, C.I. (C.I.); De-Koning, H.J. (Harry J.); Novello, S. (S.); Saghir, Z. (Zaigham); Saghir, G. (Giuseppe); Rzyman, W. (Witold); Bertolaccini, L. (Luca); Fiestas-Navarrete, L. (Lucía); Veronesi, G. (Giulia); Maisonneuve, P. (Patrick); Peled, N. (Nir); Consonni, D. (Dario); Oudkerk, M. (Matthijs); Novellis, P. (Pierluigi); Aalst, C. (Carlijn) van der; Shemesh, J. (Joseph); Tammemagi, M.C. (Martin C.); Devaraj, A. (Anand); Iavicoli, S. (Sergio); Yip, R. (Rowena); Zulueta, J. (Javier); Murray, R.L. (Rachael L.)Lung cancer screening (LCS) with low-dose computed tomography (LDCT) was demonstrated in the National Lung Screening Trial (NLST) to reduce mortality from the disease. European mortality data has recently become available from the Nelson randomised controlled trial, which confirmed lung cancer mortality reductions by 26% in men and 39–61% in women. Recent studies in Europe and the USA also showed positive results in screening workers exposed to asbestos. All European experts attending the “Initiative for European Lung Screening (IELS)”—a large international group of physicians and other experts concerned with lung cancer—agreed that LDCT-LCS should be implemented in Europe. However, the economic impact of LDCT-LCS and guidelines for its effective and safe implementation still need to be formulated. To this purpose, the IELS was asked to prepare recommendations to implement LCS and examine outstanding issues. A subgroup carried out a comprehensive literature review on LDCT-LCS and presented findings at a meeting held in Milan in November 2018. The present recommendations reflect that consensus was reached.